Skin expression data from psoriasis patients treated with IL-17A inhibitor

Psoriasis is a chronic, recurrent, inflammatory systemic disease that affects approximately 2-3% of the population worldwide. IL-17A plays a key pathogenic role in psoriasis, and IL-17A antigen have emerged as first-line agents for the treatment of moderate-to-severe plaque psoriasis.However, the associated mechanism underlying treatment-associated adverse and psoriasis relapse has not been reported The study samples are from psoriasis patients treated with anti-IL-17A inhibitor. Skin samples consist of baseline, post-treatment, and recurrent, resulting in a total of 40 samples. Gene expression profiling analysis of RNA-seq data for different time points.